Yep, would imagine people taking positions. It's less than a month away from Phase 2 results. If it's a success, it's one pivotal registration trial(and PK study) away from coming to market in the US and EU.
If you assume as Fifty One Capital have done; that Presendin will take a 40% share of the Total Addressable Market of $1.6B. Then peak sales are $640 million. Attach a 3-4 multiplier in terms of valuation, and you're left with a possible transaction value of $2B+ for the IIH product alone.
Lots of assumptions in the model, but at a $60 million market cap, it's becoming a very attractive proposition for long term investors.
Fifty one capital podcast episode on Invex, page-6
Add IXC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $4.885M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 24 | 6.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.7¢ | 7950 | 1 |
View Market Depth
| Last trade - 16.12pm 04/07/2024 (20 minute delay) ? |
| IXC (ASX) Chart |
Day chart unavailable